ArticleJournal of gastrointestinal oncology2026
Independent prognostic value of tumor deposits in stage III colorectal cancer: a large-scale systematic review and meta-analysis.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The study aims to systematically evaluate the prognostic value of tumor deposits (TDs) in patients with stage III colorectal cancer (CRC), clarify their impact on long-term oncologic outcomes, and provide evidence-based medicine to optimize CRC tumor-node-metastasis (TNM) staging and guide individualized treatment decisions. Methods: A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, ScienceDirect, and Web of Science databases to identify studies investigating the association between TDs status and prognosis in stage III CRC patients, published from database inception to December 31, 2025. Two independent researchers performed literature screening, data extraction, and quality assessment. Statistical analyses were conducted using R software (version 4.4.1). The primary outcomes were 5-year overall survival (OS) and 5-year disease-free survival (DFS). Results: A total of 18 high-quality studies involving 236,867 patients were included, comprising 16 non-randomized controlled studies and two randomized controlled trials (RCTs). Meta-analysis results demonstrated that patients with both TDs positivity and lymph node positivity (TD+LN+) had significantly poorer 5-year OS compared to those with TDs negativity but lymph node positivity (TD-LN+) [relative risk (RR) =1.58, 95% confidence interval (CI): 1.50-1.65, I Conclusions: This study confirms that TDs are independently associated with worse prognosis in patients with stage III CRC. TD+LN+ patients exhibit significantly poorer long-term survival (5-year OS and DFS) compared to those with lymph node positivity alone, while TD+LN- (N1c stage) patients have a prognostic risk intermediate between N1 and N2 stages. The current TNM staging system fails to fully integrate the prognostic value of TDs, particularly in lymph node-positive patients. We recommend optimizing the staging schema and incorporating TDs status into clinical risk stratification to develop individualized intensive treatment strategies for high-risk TDs-positive patients, thereby improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.